These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 34920374)

  • 1. Antibody response to SARS-CoV-2 for more than one year - kinetics and persistence of detection are predominantly determined by avidity progression and test design.
    Scheiblauer H; Nübling CM; Wolf T; Khodamoradi Y; Bellinghausen C; Sonntagbauer M; Esser-Nobis K; Filomena A; Mahler V; Maier TJ; Stephan C
    J Clin Virol; 2022 Jan; 146():105052. PubMed ID: 34920374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct anti-NP, anti-RBD and anti-Spike antibody profiles discriminate death from survival in COVID-19.
    Servian CDP; Spadafora-Ferreira M; Dos Anjos DCC; Guilarde AO; Gomes-Junior AR; Borges MASB; Masson LC; Silva JMM; de Lima MHA; Moraes BGN; Souza SM; Xavier LE; de Oliveira DCA; Batalha-Carvalho JV; Moro AM; Bocca AL; Pfrimer IAH; Costa NL; Feres VCR; Fiaccadori FS; Souza M; Gardinassi LG; Durigon EL; Romão PRT; Jorge SAC; Coelho V; Botosso VF; Fonseca SG
    Front Immunol; 2023; 14():1206979. PubMed ID: 37876932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetics of specific anti-SARS-CoV-2 IgM, IgA, and IgG responses during the first 12 months after SARS-CoV-2 infection: A prospective longitudinal study.
    Amellal H; Assaid N; Charoute H; Akarid K; Maaroufi A; Ezzikouri S; Sarih M
    PLoS One; 2023; 18(7):e0288557. PubMed ID: 37437051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of Anti-SARS-CoV-2-S2 IgG Is More Sensitive Than Anti-RBD IgG in Identifying Asymptomatic COVID-19 Patients.
    Liao B; Chen Z; Zheng P; Li L; Zhuo J; Li F; Li S; Chen D; Wen C; Cai W; Wu S; Tang Y; Duan L; Wei P; Chen F; Yuan J; Yang J; Feng J; Zhao J; Zhao J; Sun B; Zhu A; Li Y; Tang X
    Front Immunol; 2021; 12():724763. PubMed ID: 34489978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days.
    Xu QY; Xue JH; Xiao Y; Jia ZJ; Wu MJ; Liu YY; Li WL; Liang XM; Yang TC
    Front Immunol; 2021; 12():786554. PubMed ID: 35003104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid, early, and potent Spike-directed IgG, IgM, and IgA distinguish asymptomatic from mildly symptomatic COVID-19 in Uganda, with IgG persisting for 28 months.
    Serwanga J; Ankunda V; Sembera J; Kato L; Oluka GK; Baine C; Odoch G; Kayiwa J; Auma BO; Jjuuko M; Nsereko C; Cotten M; Onyachi N; Muwanga M; Lutalo T; Fox J; Musenero M; Kaleebu P;
    Front Immunol; 2023; 14():1152522. PubMed ID: 37006272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response kinetics of different classes of antibodies to SARS-CoV2 infection in the Japanese population: The IgA and IgG titers increased earlier than the IgM titers.
    Kurano M; Morita Y; Nakano Y; Yokoyama R; Shimura T; Qian C; Xia F; He F; Zheng L; Ohmiya H; Kishi Y; Okada J; Yoshikawa N; Nakajima K; Nagura Y; Okazaki H; Jubishi D; Moriya K; Seto Y; Yasui F; Kohara M; Wakui M; Kawamura T; Kodama T; Yatomi Y
    Int Immunopharmacol; 2022 Feb; 103():108491. PubMed ID: 34954559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and antibody characteristics reveal diverse signatures of severe and non-severe SARS-CoV-2 patients.
    Wang H; Yan D; Li Y; Gong Y; Mai Y; Li B; Zhu X; Wan X; Xie L; Jiang H; Zhang M; Sun M; Yao Y; Zhu Y
    Infect Dis Poverty; 2022 Feb; 11(1):15. PubMed ID: 35109926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repeated SARS-CoV-2 vaccination in cancer patients treated with immune checkpoint inhibitors: induction of high-avidity anti-RBD neutralizing antibodies.
    Caruso T; Salani F; Catanese S; Pratesi F; Mercinelli C; Motta G; Genovesi V; Bonato A; Sara G; Masi G; Migliorini P
    Int J Clin Oncol; 2023 Mar; 28(3):363-369. PubMed ID: 36689013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimisation and Validation of a conventional ELISA and cut-offs for detecting and quantifying anti-SARS-CoV-2 Spike, RBD, and Nucleoprotein IgG, IgM, and IgA antibodies in Uganda.
    Oluka GK; Namubiru P; Kato L; Ankunda V; Gombe B; Cotten M; ; Musenero M; Kaleebu P; Fox J; Serwanga J
    Front Immunol; 2023; 14():1113194. PubMed ID: 36999017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the correlation between the access SARS-CoV-2 IgM and IgG II antibody tests with the SARS-CoV-2 surrogate virus neutralization test.
    Kitagawa Y; Imai K; Matsuoka M; Fukada A; Kubota K; Sato M; Takada T; Noguchi S; Tarumoto N; Maesaki S; Takeuchi S; Maeda T
    J Med Virol; 2022 Jan; 94(1):335-341. PubMed ID: 34524695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methodological approaches to optimize multiplex oral fluid SARS-CoV-2 IgG assay performance and correlation with serologic and neutralizing antibody responses.
    Pisanic N; Antar AAR; Kruczynski KL; Gregory Rivera M; Dhakal S; Spicer K; Randad PR; Pekosz A; Klein SL; Betenbaugh MJ; Detrick B; Clarke W; Thomas DL; Manabe YC; Heaney CD
    J Immunol Methods; 2023 Mar; 514():113440. PubMed ID: 36773929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients.
    Isho B; Abe KT; Zuo M; Jamal AJ; Rathod B; Wang JH; Li Z; Chao G; Rojas OL; Bang YM; Pu A; Christie-Holmes N; Gervais C; Ceccarelli D; Samavarchi-Tehrani P; Guvenc F; Budylowski P; Li A; Paterson A; Yue FY; Marin LM; Caldwell L; Wrana JL; Colwill K; Sicheri F; Mubareka S; Gray-Owen SD; Drews SJ; Siqueira WL; Barrios-Rodiles M; Ostrowski M; Rini JM; Durocher Y; McGeer AJ; Gommerman JL; Gingras AC
    Sci Immunol; 2020 Oct; 5(52):. PubMed ID: 33033173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid decline of neutralizing antibodies is associated with decay of IgM in adults recovered from mild COVID-19.
    Harrington WE; Trakhimets O; Andrade DV; Dambrauskas N; Raappana A; Jiang Y; Houck J; Selman W; Yang A; Vigdorovich V; Yeung W; Haglund M; Wallner J; Oldroyd A; Hardy S; Stewart SWA; Gervassi A; Van Voorhis W; Frenkel L; Sather DN
    Cell Rep Med; 2021 Apr; 2(4):100253. PubMed ID: 33842901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TOP-Plus Is a Versatile Biosensor Platform for Monitoring SARS-CoV-2 Antibody Durability.
    Racine-Brzostek SE; Karbaschi M; Gaebler C; Klasse PJ; Yee J; Caskey M; Yang HS; Hao Y; Sukhu A; Rand S; Chadburn A; Shi Y; Zuk R; Nussenzweig MC; Cushing MM; Zhao Z
    Clin Chem; 2021 Sep; 67(9):1249-1258. PubMed ID: 33914041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific and neutralizing antibodies in recovered COVID-19 patients.
    Chansaenroj J; Yorsaeng R; Puenpa J; Wanlapakorn N; Chirathaworn C; Sudhinaraset N; Sripramote M; Chalongviriyalert P; Jirajariyavej S; Kiatpanabhikul P; Saiyarin J; Soudon C; Thienfaidee O; Ayuthaya TPN; Brukesawan C; Intharasongkroh D; Chaiwanichsiri D; Issarasongkhram M; Kitphati R; Mungaomklang A; Thitithanyanont A; Nagavajara P; Poovorawan Y
    PLoS One; 2022; 17(4):e0267102. PubMed ID: 35446889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A SARS-CoV-2 Label-Free Surrogate Virus Neutralization Test and a Longitudinal Study of Antibody Characteristics in COVID-19 Patients.
    Luo YR; Yun C; Chakraborty I; Wu AHB; Lynch KL
    J Clin Microbiol; 2021 Jun; 59(7):e0019321. PubMed ID: 33827900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous Measurement of IgM and IgG Antibodies to SARS-CoV-2 Spike, RBD, and Nucleocapsid Multiplexed in a Single Assay on the xMAP INTELLIFLEX DR-SE Flow Analyzer.
    Cameron A; Bohrhunter JL; Porterfield CA; Mangat R; Karasick MH; Pearson Z; Angeloni S; Pecora ND
    Microbiol Spectr; 2022 Apr; 10(2):e0250721. PubMed ID: 35389244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19?
    Scaggs Huang F
    J Pediatric Infect Dis Soc; 2022 Apr; 11(4):126. PubMed ID: 35394545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-Receptor-Binding Domain Immunoglobulin G Antibody as a Predictor of Seropositivity for Anti-SARS-CoV-2 Neutralizing Antibody.
    Xue JH; Wang YJ; Li W; Li QL; Xu QY; Niu JJ; Liu LL
    Arch Pathol Lab Med; 2022 Jul; 146(7):814-821. PubMed ID: 35380612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.